AKAM is pivoting toward high-growth cloud infrastructure and AI compute, anchored by a multi-year, multi-billion-dollar customer commitment, while WEAV is in a pending take-private acquisition that caps near-term upside. AKAM is a large-cap technology infrastructure leader under near-term margin pressure, whereas WEAV is a small-cap healthcare software provider whose share price is now anchored to an agreed buyout price.
AKAM is a large-cap cloud, security, and content delivery provider with a marquee artificial intelligence (AI) cloud contract, while EVH is a small-cap healthcare services company in an early-stage profitability turnaround. AKAM delivered in-line quarterly results but guided below consensus for the near term; EVH reported accelerating revenue growth but remains unprofitable on a net income basis.
Software demand is broadening. Annual Contract Value (ACV), a measure of software bookings, grew 17% year over year in Q3 2026, driven by deeper adoption across large pharmaceutical accounts, biotech, and a fast-emerging materials science customer base. A hosted licensing shift is resetting revenue recognition. Hosted revenue rose 49% and reached 45% of software revenue, trading near-term reported revenue for more predictable, ratable income and supporting the goal of positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) by the end of 2028.
The central target of $33 is the average of the verified analyst price targets that sit above the current share price, not a published Street consensus. Five current targets were reviewed, spanning roughly $29 to $36 ; the overall mean of all five is about $32 .
SDGR shares climbed roughly 13% over the trailing 30 days, from about $26.39 to $29.82, though the period featured a sharp mid-October pullback followed by a strong recovery. The move extends a broader advance, with shares up approximately 64% over the last quarter after a powerful September rally.
DOCS dropped -3.62% to $31.98 from a $33.18 prior close during Friday's regular session. The move follows fiscal Q2 FY2027 earnings released after Thursday's close: revenue ($174.5M) and EPS ($0.36) beat, but adjusted EBITDA fell 12% year-over-year and margin compressed to 51% from 60% on surging AI spending, overshadowing the beat.
Carlsmed (CARL) dropped -6.07% intraday during regular trading, sliding from a prior close of $15.32 to $14.39. No verified news or fundamental catalyst found. The decline is likely profit-taking after the stock's sharp +11.7% surge on Nov 4, consistent with its roughly 2.5% average daily swing.
Omada Health (OMDA) fell from its previous close of $18.95 to $15.49, a -18.26% drop, during regular trading hours. The move followed the Nov. 5 after-close Q3 report: despite beating estimates (EPS $0.10 vs. $0.04 expected; revenue $91.3M vs. $86.9M) and raising full-year guidance, investors sold the news on softer Q4 enrollment and GLP-1 coverage uncertainty.
DOCS slid -4.25% in regular trading, falling from a $33.18 prior close to $31.77, extending the decline that began after hours. The drop follows fiscal Q2 2027 results reported after the Nov 5 close: revenue and adjusted EPS beat estimates, but margin compression and slowing growth drove the selling.
CareCloud reported third-quarter 2026 revenue of $33.7 million, up about 9% from $31.1 million a year earlier. GAAP (Generally Accepted Accounting Principles) net income reached a record $4.7 million, up 54% year over year, marking the company's 10th straight profitable quarter.
Health Catalyst reported third quarter 2026 revenue of $56.3 million, above its guided range of $55 million to $56 million and ahead of the roughly $55.4 million consensus estimate. Revenue still declined 26% year over year from $76.3 million, reflecting the July 31, 2026 divestiture of its Vitalware business and continued migration-related client churn.
Definitive Healthcare (DH) reported third-quarter 2026 revenue of $54.7 million , down about 9% from $60.0 million a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $15.8 million , above the high end of the company's guidance range.
Third quarter 2026 revenue reached $91.3 million , up 34% year over year and above consensus estimates near $86–87 million. Omada swung to a GAAP (generally accepted accounting principles) net profit of $7.0 million , or $0.10 per diluted share , versus a net loss of $0.06 per share a year earlier.
Total revenue reached $94.9 million , up 4% year over year on a continuing operations basis for the third quarter ended September 30, 2026. Software revenue grew 11% to $48.8 million , marking the company's first double-digit organic software growth quarter in two years.
Privia Health reported third-quarter 2026 revenue of $656.96 million, up 13.2% year over year and roughly 7.5% above the consensus estimate of $611.3 million. Adjusted earnings per share (EPS) came in at $0.21, below the consensus estimate of $0.24, marking an 11.8% miss despite the strong top line.
Doximity reported fiscal second quarter 2027 revenue of $174.5 million , up 3.6% year over year and ahead of the consensus estimate of roughly $171.1 million. Adjusted earnings per share (EPS) of $0.36 came in line with analyst expectations of about $0.35.
Total revenue rose 19% year over year to $64.5 million, driven by software growth and a milestone payment in drug discovery. Software revenue reached $38.2 million, with hosted revenue climbing 49% to $17.2 million.
AI-driven product expansion is a central forward theme, including a next-generation, AI-powered laboratory data analysis solution that could broaden the company's addressable use cases beyond core teleconsultations. Regional and U.S. growth strategy positions MNDR to diversify beyond its Singapore home market, with Southeast Asia and the United States representing key medium-term expansion frontiers.
The central target discussed here is $1.00 , a round-number psychological milestone rather than an analyst consensus; it reflects public discussion and a dated single rating, not a verified analyst aggregate. With the stock recently closing near $0.90, reaching $1.00 would require a move of roughly 11% — modest in percentage terms but still significant for a deeply distressed micro-cap.
Mobile-health Network Solutions shares fell roughly 30% over the last 30 days, declining from about $1.29 to near $0.90. The move was shaped by extreme low-float, penny-stock volatility, including a sharp spike-and-reversal in mid-October.